参考文献/References:
[1]Wendt FR,Koller D,Pathak GA,et al.Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use[J].Clin Pharmacol Ther,2021,110(3):777-785.[2]Almeida N,Rodriguez J,Pla Parada I,et al.Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database[J].Cancers (Basel),2021,13(24):6224.[3]Parichehreh-Dizaji S,Samimi H,Asadolahpour E,et al.Establishment of biobank facility at Endocrinology and Metabolism Research Institute of Iran: experiences, challenges, and future outlook[J].J Diabetes Metab Disord,2021,20(1):1081-1084. [4]Ostrom QT,Devine K,Fulop J,et al.Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology[J].Neurooncol Pract,2017,4(4):220-228. [5]Milton AD,Almazroue H,Jin Y,et al.DDAH1 SNP rs480414 that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia results in lower nitric oxide production in neonatal cord blood-derived lymphoblastoid cell lines[J].J Neonatal Perinatal Med,2022,15(1):113-121. [6]Dong SS,Zhu DL,Zhou XR,et al.An Intronic Risk SNP rs12454712 for Central Obesity Acts As an Allele-Specific Enhancer To Regulate BCL2 Expression[J].Diabetes,2021,70(8):1679-1688. [7]Nyg?覽rd L,Laine AP,Kiviniemi M,et al.Tri-SNP polymorphism in the intron of HLA-DRA1 affects type 1 diabetes susceptibility in the Finnish population[J].Hum Immunol,2021,82(12):912-916. [8]Zhang Z,Liu X,Li L,et al.SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation[J].EMBO J,2021,40(19):e107974.[9]Lazzari C,Spagnolo CC,Ciappina G,et al.Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives[J].Curr Oncol,2023,30(4):3684-3696.[10]满秋红,于农,闫飞,等.我国生物样本库建设现状与未来发展的思考[J].中国医药生物技术,2018,13(4):289-293.[11]Fransson MN,Rial-Sebbag E,Brochhausen M,et al.Toward a common language for biobanking[J].Eur J Hum Genet,2015,23(1):22-28. [12]中国国家标准化管理委员会,国家市场监督管理总局.生物样本库质量和能力通用要求:GB/T 37864-2019[S].北京:中国标准出版社,2019.[13]中华人民共和国国家质量监督检验检疫总局,中国国家标准化管理委员会.实验室生物安全通用要求:GB 19489-2008[S].北京:中国标准出版社,2008.[14]国家卫生和计划生育委员会.病原微生物实验室生物安全通用准则:WS 233-2017[S].北京:国家卫生和计划生育委员会,2017.[15]Kuriyama S,Yaegashi N,Nagami F,et al.The Tohoku Medical Megabank Project:Design and Mission[J].J Epidemiol,2016,26(9):493-511.[16]Minegishi N,Nishijima I,Nobukuni T,et al.Biobank Establishment and Sample Management in the Tohoku Medical Megabank Project[J].Tohoku J Exp Med,2019,248(1):45-55.[17]Evans JR,Akee RK,Chanana S,et al.National Cancer Institute (NCI) Program for Natural Product Discovery: Exploring NCI-60 Screening Data of Natural Product Samples with Artificial Neural Networks[J].ACS Omega,2023,8(10):9250-9256. [18]Elliott P,Peakman TC,UK Biobank.The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine[J].International Journal of Epidemiology,2008,37(2):234-244.[19]Ramírez J,van Duijvenboden S,Young WJ,et al.Analysing electrocardiographic traits and predicting cardiac risk in UK biobank[J].JRSM Cardiovasc Dis,2021,10:20480040211023664.[20]余其澳,宋欢,汪晓东,等.英国生物样本库（UK Biobank）在结直肠癌临床研究中的应用[J].中华结直肠疾病电子杂志,2021,10(4):351-356.
相似文献/References:
[1]李书有.中晚期肝癌的非手术综合治疗[J].医学信息,2022,35(09):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
LI Shu-you.Non-surgical Comprehensive Treatment for Advanced Liver Cancer[J].Journal of Medical Information,2022,35(03):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
[2]吴玉斌,李先明.涎腺粘液表皮样癌与腺样囊性癌基因突变及靶向治疗研究[J].医学信息,2022,35(11):64.[doi:10.3969/j.issn.1006-1959.2022.11.018]
WU Yu-bin,LI Xian-ming.Study on Gene Mutation and Targeted Therapy of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of Salivary Gland[J].Journal of Medical Information,2022,35(03):64.[doi:10.3969/j.issn.1006-1959.2022.11.018]
[3]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Journal of Medical Information,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[4]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Journal of Medical Information,2018,31(03):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[5]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,32(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Journal of Medical Information,2019,32(03):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
[6]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,32(17):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(03):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
[7]穆红茹.中晚期宫颈癌的非手术治疗进展[J].医学信息,2022,35(15):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
MU Hong-ru.Advances in Nonsurgical Treatment of Cervical Cancer in the Middle and Late Stage[J].Journal of Medical Information,2022,35(03):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
[8]唐武兵,杨 文,陈健智,等.尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究[J].医学信息,2019,32(20):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
TANG Wu-bing,YANG Wen,CHEN Jian-zhi,et al.Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2019,32(03):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
[9]秦天宇,王立春.椎管内肿瘤手术方式的研究[J].医学信息,2019,32(22):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
QIN Tian-yu,WANG Li-chun.Study on Surgical Methods of Intraspinal Tumor[J].Journal of Medical Information,2019,32(03):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
[10]李芮蝶,朱雪莉,陈 鑫.三阴乳腺癌分型与临床药物治疗的研究[J].医学信息,2020,33(05):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
LI Rui-die,ZHU Xue-li,CHEN Xin.Study on the Classification of Triple Negative Breast Cancer and Clinical Drug Therapy[J].Journal of Medical Information,2020,33(03):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]